BRIEF published on 12/11/2025 at 23:05, 4 days 13 hours ago Xenetic Biosciences Adjourns 2025 Annual Stockholders Meeting Xenetic Biosciences Stockholders Meeting Voting Instructions Quorum 2025 Adjournment
PRESS RELEASE published on 12/11/2025 at 23:00, 4 days 14 hours ago Xenetic Biosciences, Inc. Announces Adjournment of 2025 Annual Meeting Xenetic Biosciences, Inc. adjourns 2025 Annual Meeting of Stockholders due to lack of quorum. Stockholders urged to vote before reconvened meeting on January 8, 2026 Xenetic Biosciences Stockholders Quorum Proxy Vote 2025 Annual Meeting
BRIEF published on 11/19/2025 at 14:50, 26 days 22 hours ago Xenetic Biosciences Extends Collaboration with Scripps Research Cancer Treatment Biopharmaceutical DNase I CAR-T Therapy Scripps Research
PRESS RELEASE published on 11/19/2025 at 14:45, 26 days 22 hours ago Xenetic Biosciences, Inc. Extends Research and Development Collaboration with Institute Investigator at Scripps Research to Advance DNase Platform Xenetic Biosciences extends collaboration with Scripps Research to advance DNase-based immuno-oncology treatment for cancers Xenetic Biosciences Immuno-oncology DNase I CAR-T Therapy Scripps Research
BRIEF published on 11/13/2025 at 14:50, 1 month 2 days ago Xenetic Biosciences Reports Q3 2025 Financial Results Financial Results Revenue Increase Clinical Trials Pancreatic Carcinoma DNase Technology
PRESS RELEASE published on 11/13/2025 at 14:45, 1 month 2 days ago Xenetic Biosciences, Inc. Reports Third Quarter 2025 Financial Results Xenetic Biosciences, Inc. reports Q3 2025 financial results, focuses on DNase-based technology for cancer treatment. Secured $3.9 million from offering, advancing collaborations Xenetic Biosciences Cancer Treatment Collaborations DNase Technology Q3 2025 Financial Results
BRIEF published on 10/10/2025 at 15:35, 2 months 5 days ago Xenetic Biosciences Announces $4.5 Million Stock Offering Xenetic Biosciences Biopharmaceutical Immuno-oncology Stock Offering Canaccord Genuity
PRESS RELEASE published on 10/10/2025 at 15:30, 2 months 5 days ago Xenetic Biosciences, Inc. Announces Pricing of $4.5 Million Underwritten Offering of Common Stock Xenetic Biosciences, Inc. announces pricing of underwritten stock offering, aiming to raise $4.5 million for immuno-oncology technologies. Canaccord Genuity acts as bookrunner Xenetic Biosciences Stock Offering Immuno-oncology Technologies Canaccord Genuity S-3 Registration Statement
BRIEF published on 08/13/2025 at 14:05, 4 months 2 days ago Xenetic Biosciences Reports Q2 2025 Financial Results Financial Results Xenetic Biosciences Q2 2025 DNase I Development Partnership Expansions
PRESS RELEASE published on 08/13/2025 at 14:00, 4 months 2 days ago Xenetic Biosciences, Inc. Reports Second Quarter 2025 Financial Results Xenetic Biosciences, Inc. reports Q2 2025 results, expands partnership with The Scripps Research Institute for DNase I with CAR T-cell therapies and ends quarter with $4.8M cash Financial Results Xenetic Biosciences DNase I The Scripps Research Institute CAR T-cell Therapies
Published on 12/16/2025 at 13:00, 3 minutes ago Abasca Resources Provides Exploration Update at its Loki Flake Graphite Deposit and Granting Stock Option
Published on 12/16/2025 at 12:00, 1 hour 3 minutes ago Tokenwell Plans to Establish U.S. Subsidiary in Dallas, Texas, to Expand its Presence in the Growing Digital Asset Hub
Published on 12/16/2025 at 12:00, 1 hour 3 minutes ago CTT Pharma's Scientists Publish Peer-Reviewed Paper in the Journal of Drug Delivery and Therapeutics
Published on 12/16/2025 at 12:00, 1 hour 3 minutes ago Snowline Gold Awards Key Contracts and Commences Prefeasibility Study on its Flagship Rogue Project, Yukon
Published on 12/16/2025 at 09:05, 3 hours 58 minutes ago Nano One Receives C$10.9M from Financing and Government Programs
Published on 12/16/2025 at 12:55, 8 minutes ago Banyan Group's Garrya Mu Cang Chai Opens in a National Heritage Site in Northern Vietnam
Published on 12/16/2025 at 12:22, 40 minutes ago REPLOID Group AG: HEROSAN launches crowdfunding campaign
Published on 12/16/2025 at 12:05, 58 minutes ago BRP Announces Appointment of Denis Le Vot as President and Chief Executive Officer
Published on 12/16/2025 at 12:00, 1 hour 3 minutes ago DATAGROUP initiates delisting procedure on the Munich Stock Exchange
Published on 12/16/2025 at 11:49, 1 hour 13 minutes ago Strategic Investment: CANSOUL acquires stake in SYNBIOTIC
Published on 12/16/2025 at 08:30, 4 hours 33 minutes ago Cie du Bois Sauvage: Buy back of own shares – week from 08/12/2025 to 12/12/2025
Published on 12/15/2025 at 22:36, 14 hours 27 minutes ago Disclosure of trading in own shares between December 1st and December 5th, 2025
Published on 12/15/2025 at 18:30, 18 hours 33 minutes ago MCH PRIVATE EQUITY AND EURAZEO ENTER INTO AN EXCLUSIVE AGREEMENT WITH ARDIAN FOR THE SALE OF THEIR MAJORITY STAKE IN FERMAX
Published on 12/15/2025 at 18:05, 18 hours 58 minutes ago Covivio - Treasury shares transactions between December 8th , 2025 and December 12th, 2025
Published on 12/15/2025 at 17:45, 19 hours 17 minutes ago ENGIE strengthens the resilience of the Belgian electricity system with new flexible capacities
